title: Ledipasvir and sofosbuvir for recurrent hepatitis C after liver transplantation.
abstract: Management of recurrent hepatitis C following liver transplantation still remains a challenge. Here, we report five patients who achieved viral responses following combined treatment with ledipasvir and sofosbuvir. All the patients received tacrolimus for immunosuppression. No dose adjustment was made before the ledipasvir and sofosbuvir therapy. All completed the intended 12-week treatment course with the full dose of ledipasvir and sofosbuvir. There were no significant adverse events greater than grade 2. During the study period, no acute rejection episodes were detected. The trough levels of tacrolimus were maintained stably. Hepatitis C virus RNA was not detected at week 12 in any of the patients. Based on the findings from this pilot study, combined ledipasvir and sofosbuvir therapy for 12 weeks is effective and safe for living - donor liver transplantation recipients with recurrence of hepatitis C virus.
authors.affiliation: Departments of Transplantation/Pediatric Surgery and Gastroenterology and Hepatology, Postgraduate School of Life Science, Kumamoto University.
authors.forename: Yuki
authors.initials: Y
authors.lastname: Oya
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Sugawara
authors.forename: Takehisa
authors.initials: T
authors.lastname: Watanabe
authors.forename: Yoko
authors.initials: Y
authors.lastname: Yoshimaru
authors.forename: Masaki
authors.initials: M
authors.lastname: Honda
authors.forename: Shintaro
authors.initials: S
authors.lastname: Hashimoto
authors.forename: Daiki
authors.initials: D
authors.lastname: Yoshii
authors.forename: Kaori
authors.initials: K
authors.lastname: Isono
authors.forename: Shintaro
authors.initials: S
authors.lastname: Hayashida
authors.forename: Hidekazu
authors.initials: H
authors.lastname: Yamamoto
authors.forename: Motohiko
authors.initials: M
authors.lastname: Tanaka
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Sasaki
authors.forename: Yukihiro
authors.initials: Y
authors.lastname: Inomata
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D005260:Female; D005449:Fluorenes / Q000627:therapeutic use*; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000601:surgery; D006801:Humans; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D000069474:Sofosbuvir / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D001562:Benzimidazoles; D005449:Fluorenes; C586541:ledipasvir; D000069474:Sofosbuvir